Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fatty Liver | 4 | 2026 | 77 | 1.390 |
Why?
|
| Liver Transplantation | 4 | 2024 | 56 | 0.970 |
Why?
|
| Liver | 7 | 2026 | 471 | 0.960 |
Why?
|
| Biomarkers | 6 | 2026 | 782 | 0.910 |
Why?
|
| Zellweger Syndrome | 2 | 2021 | 3 | 0.900 |
Why?
|
| Liver Diseases | 2 | 2024 | 52 | 0.890 |
Why?
|
| Cystic Fibrosis | 1 | 2024 | 34 | 0.840 |
Why?
|
| Hepatitis, Autoimmune | 3 | 2021 | 5 | 0.810 |
Why?
|
| Digestive System Abnormalities | 1 | 2022 | 3 | 0.750 |
Why?
|
| Intestinal Diseases | 1 | 2022 | 11 | 0.750 |
Why?
|
| Cysts | 1 | 2022 | 23 | 0.740 |
Why?
|
| Osteogenesis Imperfecta | 1 | 2021 | 3 | 0.690 |
Why?
|
| Liver Failure, Acute | 1 | 2021 | 4 | 0.680 |
Why?
|
| Heterozygote | 1 | 2021 | 69 | 0.670 |
Why?
|
| Child | 14 | 2026 | 2327 | 0.640 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 123 | 0.630 |
Why?
|
| End Stage Liver Disease | 1 | 2019 | 9 | 0.600 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 4 | 2024 | 75 | 0.580 |
Why?
|
| Health Status Disparities | 1 | 2019 | 66 | 0.570 |
Why?
|
| African Americans | 2 | 2021 | 353 | 0.540 |
Why?
|
| Crohn Disease | 2 | 2021 | 32 | 0.520 |
Why?
|
| Colitis, Ulcerative | 2 | 2021 | 31 | 0.520 |
Why?
|
| Adolescent | 12 | 2026 | 3223 | 0.500 |
Why?
|
| Cholangitis, Sclerosing | 3 | 2020 | 4 | 0.480 |
Why?
|
| Pediatric Obesity | 3 | 2026 | 79 | 0.480 |
Why?
|
| Humans | 21 | 2026 | 28983 | 0.430 |
Why?
|
| Female | 15 | 2026 | 15682 | 0.340 |
Why?
|
| Recurrence | 3 | 2021 | 327 | 0.340 |
Why?
|
| Case-Control Studies | 4 | 2026 | 739 | 0.330 |
Why?
|
| Phenotype | 3 | 2021 | 686 | 0.330 |
Why?
|
| Male | 15 | 2026 | 13978 | 0.320 |
Why?
|
| Endotoxins | 1 | 2026 | 30 | 0.240 |
Why?
|
| Keratin-18 | 1 | 2025 | 3 | 0.230 |
Why?
|
| ROC Curve | 1 | 2025 | 144 | 0.230 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2024 | 4 | 0.220 |
Why?
|
| Paracentesis | 1 | 2024 | 5 | 0.220 |
Why?
|
| Lipoproteins, HDL | 1 | 2024 | 41 | 0.220 |
Why?
|
| Gastrostomy | 1 | 2024 | 8 | 0.220 |
Why?
|
| Lipoproteins, LDL | 1 | 2024 | 42 | 0.220 |
Why?
|
| Blood Proteins | 1 | 2024 | 68 | 0.220 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2024 | 67 | 0.210 |
Why?
|
| Terminology as Topic | 1 | 2024 | 64 | 0.210 |
Why?
|
| MicroRNAs | 2 | 2025 | 302 | 0.210 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 74 | 0.200 |
Why?
|
| Cohort Studies | 3 | 2024 | 898 | 0.200 |
Why?
|
| Infant | 3 | 2021 | 1049 | 0.190 |
Why?
|
| gamma-Glutamyltransferase | 2 | 2020 | 18 | 0.190 |
Why?
|
| Stomach | 1 | 2022 | 43 | 0.180 |
Why?
|
| Cholic Acid | 1 | 2021 | 1 | 0.180 |
Why?
|
| Bile Acids and Salts | 1 | 2021 | 25 | 0.170 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2021 | 4 | 0.170 |
Why?
|
| Calbindin 2 | 1 | 2021 | 3 | 0.170 |
Why?
|
| Whole Exome Sequencing | 1 | 2021 | 9 | 0.170 |
Why?
|
| Dwarfism | 1 | 2021 | 27 | 0.170 |
Why?
|
| Bone Density Conservation Agents | 1 | 2021 | 18 | 0.170 |
Why?
|
| Disease Management | 1 | 2021 | 91 | 0.170 |
Why?
|
| Risk Assessment | 2 | 2020 | 631 | 0.170 |
Why?
|
| Mitochondrial Myopathies | 1 | 2020 | 1 | 0.170 |
Why?
|
| Gonadal Dysgenesis, 46,XX | 1 | 2020 | 1 | 0.170 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2020 | 22 | 0.170 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2020 | 19 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2021 | 924 | 0.160 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 44 | 0.160 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2020 | 25 | 0.160 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2020 | 4 | 0.160 |
Why?
|
| Risk Factors | 3 | 2021 | 2133 | 0.160 |
Why?
|
| Gastroenterology | 1 | 2020 | 15 | 0.160 |
Why?
|
| Seasons | 1 | 2020 | 94 | 0.150 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 3 | 0.150 |
Why?
|
| Georgia | 1 | 2019 | 22 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2020 | 128 | 0.150 |
Why?
|
| Pediatrics | 1 | 2020 | 116 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 150 | 0.140 |
Why?
|
| L-Selectin | 1 | 2017 | 11 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 676 | 0.130 |
Why?
|
| Reperfusion Injury | 1 | 2017 | 34 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 98 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 112 | 0.130 |
Why?
|
| Asia, Southeastern | 1 | 2016 | 11 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2021 | 634 | 0.120 |
Why?
|
| India | 1 | 2016 | 147 | 0.120 |
Why?
|
| Colitis | 1 | 2016 | 54 | 0.120 |
Why?
|
| United States | 1 | 2021 | 2246 | 0.110 |
Why?
|
| Disease Progression | 3 | 2021 | 479 | 0.110 |
Why?
|
| Incidence | 1 | 2016 | 573 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2021 | 2644 | 0.100 |
Why?
|
| Liver Function Tests | 2 | 2020 | 9 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 485 | 0.070 |
Why?
|
| Prognosis | 2 | 2020 | 812 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 1032 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2021 | 1196 | 0.060 |
Why?
|
| Acute-Phase Proteins | 1 | 2026 | 6 | 0.060 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2026 | 14 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2026 | 94 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2026 | 149 | 0.060 |
Why?
|
| Vascular Stiffness | 1 | 2024 | 41 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2026 | 255 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2024 | 358 | 0.050 |
Why?
|
| Sex Factors | 1 | 2024 | 470 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2023 | 26 | 0.050 |
Why?
|
| Triglycerides | 1 | 2023 | 123 | 0.050 |
Why?
|
| Peptides | 1 | 2024 | 297 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 13 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 26 | 0.040 |
Why?
|
| Graft Survival | 1 | 2021 | 29 | 0.040 |
Why?
|
| Cholangiography | 1 | 2020 | 7 | 0.040 |
Why?
|
| Bilirubin | 1 | 2020 | 11 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2020 | 36 | 0.040 |
Why?
|
| Anemia, Sideroblastic | 1 | 2020 | 2 | 0.040 |
Why?
|
| Acidosis, Lactic | 1 | 2020 | 3 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 29 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 185 | 0.040 |
Why?
|
| Edema | 1 | 2020 | 18 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 111 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 219 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 208 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 429 | 0.040 |
Why?
|
| Allergens | 1 | 2020 | 10 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2020 | 284 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 237 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 194 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 73 | 0.040 |
Why?
|
| Adult | 2 | 2021 | 8045 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 555 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2019 | 393 | 0.030 |
Why?
|
| Young Adult | 1 | 2024 | 2842 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 788 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 466 | 0.030 |
Why?
|
| Mitochondria | 1 | 2020 | 410 | 0.030 |
Why?
|
| Obesity | 1 | 2023 | 702 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 144 | 0.030 |
Why?
|
| Oklahoma | 1 | 2020 | 1058 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 2065 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 452 | 0.030 |
Why?
|
| Time Factors | 1 | 2019 | 1619 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 2427 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 1660 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 5606 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 7425 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 10710 | 0.010 |
Why?
|